Autonomix Medical, Inc.

AI-generated fair value estimate for this company.

Method: Net cash plus modest option-value approach: $5.1M cash (as of July 28, 2026) divided by 971,043 shares outstanding (~$5.25/share), plus a roughly 10% premium for pipeline optionality given issued patents and a completed GLP preclinical study.

Reasoning: Autonomix is a pre-revenue, development-stage medical device company with no product sales and a large net loss relative to its market cap, so a cash-flow DCF is not meaningful; net cash is the most defensible floor value, with a small premium for the option value of its neural-sensing catheter pipeline ahead of FDA submission.